Tenaya Therapeutics (TNYA) Share-based Compensation (2020 - 2026)
Tenaya Therapeutics (TNYA) posted quarterly Share-based Compensation of $2.2 million for Q1 2026, down 41.14% year-over-year from $3.7 million in Q1 2025, and up 123.87% quarter-over-quarter from -$9.2 million in Q4 2025.
Tenaya Therapeutics (TNYA) Share-based Compensation (2020 - 2026) Analysis & Trends
Tenaya Therapeutics' Share-based Compensation history runs 7 years deep, the most recent figure standing at $2.2 million for Q1 2026.
- In Q1 2026, Share-based Compensation fell 41.14% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at -$436000.0 (down 102.72% YoY), while the FY2025 annual figure was $7.8 million, down 52.73% from the prior year.
- Share-based Compensation for Q1 2026 stood at $2.2 million, up from -$9.2 million in the prior quarter.
- The five-year high for Share-based Compensation was $4.6 million in Q2 2024, with the low at -$9.2 million in Q4 2025.
- The 5-year median for Share-based Compensation is $3.6 million (2025), against an average of $2.7 million.
- The sharpest annual moves came in 2022 and 2025: Share-based Compensation surged 500.0% in 2022, then plunged 344.77% in 2025.
- Tenaya Therapeutics' Share-based Compensation stood at $3.2 million in 2022, then rose by 23.91% to $3.9 million in 2023, then retreated by 4.81% to $3.8 million in 2024, then tumbled by 344.77% to -$9.2 million in 2025, then jumped by 123.87% to $2.2 million in 2026.
- Business Quant data shows TNYA's Share-based Compensation at $2.2 million in Q1 2026, -$9.2 million in Q4 2025, and $2.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Tenaya Therapeutics | 151.50 Mn | 151.50 Mn | - | 1.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.70 Mn |
| Jun 30, 2026 | 1.70 Mn |
| Mar 31, 2026 | 2.20 Mn |
| Mar 31, 2026 | 2.20 Mn |
| Dec 31, 2025 | -9.20 Mn |
| Dec 31, 2025 | -9.20 Mn |
| Sep 30, 2025 | 2.93 Mn |
| Sep 30, 2025 | 2.93 Mn |
| Jun 30, 2025 | 3.64 Mn |
| Jun 30, 2025 | 3.64 Mn |
| Mar 31, 2025 | 3.73 Mn |
| Mar 31, 2025 | 3.73 Mn |
| Dec 31, 2024 | 3.76 Mn |
| Dec 31, 2024 | 3.76 Mn |
| Sep 30, 2024 | 3.91 Mn |
| Sep 30, 2024 | 3.91 Mn |
| Jun 30, 2024 | 4.61 Mn |
| Jun 30, 2024 | 4.61 Mn |
| Mar 31, 2024 | 4.22 Mn |
| Mar 31, 2024 | 4.22 Mn |